Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2006 1
2008 4
2009 1
2010 41
2011 474
2012 931
2013 1047
2014 1018
2015 928
2016 1107
2017 1346
2018 1527
2019 857
2020 29
Text availability
Article attribute
Article type
Publication date

Search Results

7,790 results
Results by year
Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Varricchi G, et al. Curr Med Chem 2018 - Review. PMID 28403786
Ipilimumab (anti-CTLA-4) is the godfather of checkpoint inhibitors, whereas several blocking monoclonal antibodies targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab, durvalumab, avelumab, and BMS-946559) have been developed. ...
Ipilimumab (anti-CTLA-4) is the godfather of checkpoint inhibitors, whereas several blocking monoclonal antibodies targeting PD-1 (ni …
Pembrolizumab (Keytruda)
Kwok G, et al. Hum Vaccin Immunother 2016 - Review. PMID 27398650 Free PMC article.
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH, et al. Clin Drug Investig 2019. PMID 30674039
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs)-cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1) monoclonal antibodies (mAbs)-either as single agents or in combination have become the standard of care for an increasing number of indications. ...
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs)-cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD- …
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)
Hwang SJE and Fernández-Peñas P. Curr Probl Dermatol 2018 - Review. PMID 29131040
With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed cell death 1 antibodies, various skin toxicities have emerged. ...
With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed cell death 1 antibodies
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
De Martin E, et al. J Hepatol 2018. PMID 29427729
This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) monoclonal antibodies (mAbs). ...
This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) and anti-cytotoxic T lymph …
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Baker KF and Isaacs JD. Ann Rheum Dis 2018 - Review. PMID 28765121
Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their application to the treatment of IMIDs....
Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their a …
7,790 results
Jump to page
Feedback